Bioventus Inc expected to post a loss of 2 cents a share - Earnings Preview

Bioventus

03/11/2023 15:49

* Bioventus Inc  BVS.OQ   BVS.O  is expected to show a fall
in
quarterly revenue when it reports  results 
    * The Durham North Carolina-based  company is expected to
report 
a 13.2% decrease in revenue to $119.004 million from $137.07
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Bioventus Inc is
for a
loss of 2 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "Hold".​
    * Wall Street's median 12-month price target for Bioventus
Inc is
$4.5​, above​ its last closing price of $3.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  0.01        0.00       0.14      Beat    
 Mar. 31 2023  -0.15       -0.15      -0.26     Missed  -73.3
 Dec. 31 2022  0.05        0.05       -0.06     Missed  -226.3
                                                        ​
 Sep. 30 2022  0.12        0.12       0.08      Missed  -34.4
 ​​Jun.        0.15        0.16       0.10      Missed  -35.9
 30 2022                                                
 Mar. 31 2022  0.05        0.05       0.04      Missed  -16.7​
 Dec. 31 2021  0.17        0.18       0.26      Beat    46.5
 Sep. 30 2021  0.14        0.14       0.25      Beat    78.6
 This summary was machine generated November 3 at 15:49 GMT.  All
figures in US dollars  unless otherwise stated